Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Baylor Research Institute
Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls.
Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls.
Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects.
Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
Age
18–64
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male patients with Fabry disease age 20-64 years old.
Healthy male controls age 20-64 years old
GLA gene mutations associated with the classic form of Fabry disease or having alpha-galactosidase A activity that is essentially zero
Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent.
Clareo Health | Androgenetic Alopecia in Fabry Disease
